日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Psychometric Properties and Meaningful Change Thresholds of the Vitiligo Area Scoring Index.

白癜风面积评分指数的心理测量特性和有意义的变化阈值

Ezzedine Khaled, Soliman Ahmed M, Camp Heidi S, Ladd Mary Kate, Pokrzywinski Robin, Coyne Karin S, Sen Rohini, Schlosser Bethanee J, Bae Jung Min, Hamzavi Iltefat

Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]

对“每日一次的upadacitinib与安慰剂治疗广泛性非节段型白癜风成人患者:一项2期、多中心、随机、双盲、安慰剂对照、剂量范围研究”的更正[eClinicalMedicine 73(2024) 102655]

Passeron, Thierry; Ezzedine, Khaled; Hamzavi, Lltefat; van Geel, Nanja; Schlosser, Bethanee J; Wu, Xiaoqiang; Huang, Xiaohong; Soliman, Ahmed M; Rosmarin, David; Harris, John E; Camp, Heidi S; Pandya, Amit G

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial

在日本类风湿关节炎患者中,对于传统合成改善病情抗风湿药疗效不佳的患者,使用upadacitinib的长期安全性和有效性:SELECT-SUNRISE随机对照试验的5年结果

Kameda, Hideto; Takeuchi, Tsutomu; Yamaoka, Kunihiro; Oribe, Motohiro; Kawano, Mitsuhiro; Konishi, Yuko; Chonan, Sumi; Ikeda, Kimitoshi; Camp, Heidi S; Tanaka, Yoshiya

Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial

乌帕替尼治疗多关节型幼年特发性关节炎患儿的药代动力学、疗效和安全性:一项开放标签1期试验的中期分析

Brunner, Hermine I; Shmagel, Anna; Horneff, Gerd; Foeldvari, Ivan; Antón, Jordi; Ramanan, Athimalaipet V; Qian, Yuli; Unnebrink, Kristina; Hao, Shuai; Camp, Heidi S; Khan, Nasser; Liu, Wei; Mohamed, Mohamed-Eslam F

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

每日一次服用upadacitinib与安慰剂治疗广泛性非节段型白癜风成人患者:一项2期、多中心、随机、双盲、安慰剂对照、剂量范围研究

Passeron, Thierry; Ezzedine, Khaled; Hamzavi, Iltefat; van Geel, Nanja; Schlosser, Bethanee J; Wu, Xiaoqiang; Huang, Xiaohong; Soliman, Ahmed M; Rosmarin, David; Harris, John E; Camp, Heidi S; Pandya, Amit G

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

SELECT-BEYOND 研究 5 年随访结果显示,对于生物制剂治疗反应不足或不耐受的类风湿性关节炎患者,upadacitinib 的疗效和安全性

Fleischmann, Roy; Meerwein, Sebastian; Charles-Schoeman, Christina; Combe, Bernard; Hall, Stephen; Khan, Nasser; Carter, Kyle M; Camp, Heidi S; Rubbert-Roth, Andrea

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

在类风湿性关节炎患者中,乌帕替尼单药治疗与甲氨蝶呤单药治疗的疗效和安全性比较:SELECT-EARLY随机对照试验5年随访结果

van Vollenhoven, Ronald; Strand, Vibeke; Takeuchi, Tsutomu; Chávez, Nilmo; Walter, Pablo Mannucci; Singhal, Atul; Swierkot, Jerzy; Khan, Nasser; Bu, Xianwei; Li, Yihan; Penn, Sara K; Camp, Heidi S; Aelion, Jacob

Disease Course, Treatment Patterns and Goals Among Patients with Non-segmental Vitiligo Across Europe and the United States

欧洲和美国非节段型白癜风患者的疾病进程、治疗模式和目标

Rosmarin, David; Soliman, Ahmed M; Marwaha, Simran; Piercy, James; Camp, Heidi S; Anderson, Peter; Ezzedine, Khaled

Health-Related Quality of Life Burden Among Adults with Vitiligo: Relationship to Disease Severity and Disease Location

白癜风成人患者的健康相关生活质量负担:与疾病严重程度和疾病部位的关系

Rosmarin, David; Soliman, Ahmed M; Piercy, James; Marwaha, Simran; Anderson, Peter; Camp, Heidi S

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

SELECT-CHOICE 研究中 Upadacitinib 对生物制剂 DMARD 难治性类风湿关节炎患者的安全性和有效性:截至第 216 周的结果

Rubbert-Roth, Andrea; Kato, Koji; Haraoui, Boulos; Rischmueller, Maureen; Liu, Yanxi; Khan, Nasser; Camp, Heidi S; Xavier, Ricardo M